Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA immunization using a non-viral promoter.

T Vanniasinkam1, S T Reddy, H C J Ertl

  • 1The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.

Virology
|October 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A perspective on ABO incompatible transplantation.

Human immunology·2026
Same author

ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV.

Metabolism: clinical and experimental·2021
Same author

Human immune responses to traditional and novel rabies vaccines.

Revue scientifique et technique (International Office of Epizootics)·2019
Same author

Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.

Atherosclerosis·2018
Same author

A short-term increase in dietary cholesterol and fat intake affects high-density lipoprotein composition in healthy subjects.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

Coronary artery disease in high risk South Asian immigrants: Role of dysfunctional HDL in risk prediction.

Indian heart journal·2017

This study demonstrates that non-viral promoters, specifically the MHC class II promoter, can be effectively used in DNA vaccines. This approach avoids the downregulation issues often seen with viral promoters, enhancing vaccine potential.

Area of Science:

  • Immunology
  • Molecular Biology
  • Vaccinology

Background:

  • DNA vaccines commonly utilize strong viral promoters for transgene expression.
  • Viral promoter efficacy in DNA vaccines can be limited by cytokine-induced downregulation, such as interferon gamma (IFN-γ).
  • IFN-γ-mediated downregulation is often triggered by CpG motifs present in viral DNA vaccine constructs.

Purpose of the Study:

  • To investigate the potential of non-viral promoters, specifically the MHC class II promoter, in DNA vaccine design.
  • To overcome IFN-γ-induced downregulation of viral promoters in DNA vaccines.
  • To enhance the activity of the MHC class II promoter using co-inoculated plasmids expressing the MHC class II transactivator (CIITA).

Main Methods:

  • Vaccine vectors were engineered to be driven by the MHC class II promoter.

Related Experiment Videos

  • Co-inoculation with plasmids expressing human MHC class II transactivator (CIITA) under the control of either the native IFN-γ-inducible CIITA type IV promoter (PIV) or a synthetic promoter.
  • Evaluation of DNA vaccine performance using non-viral promoter systems.

    • Main Results:

    • The MHC class II promoter demonstrated utility as a non-viral promoter in DNA vaccine vectors.
    • Co-inoculation strategies enhanced the activity of the MHC class II promoter.
    • The study successfully utilized a non-viral promoter, mitigating issues associated with viral promoter downregulation.

    Conclusions:

    • Non-viral promoters, such as the MHC class II promoter, represent a viable alternative for DNA vaccine development.
    • This strategy circumvents the limitations imposed by cytokine-mediated downregulation of viral promoters.
    • The findings support the development of novel DNA vaccine platforms with improved stability and efficacy.